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Six patients with myocarditis documented by biopsy, 
after a baseline right heart catheterization and echocar•
diogram, underwent treatment with azathioprine and 
prednisone. After 3 months of treatment, biopsy, right 
heart catheterization and echocardiogram were re•
peated. In addition to the immunosuppressive therapy, 
most patients received additional conventional medica•
tions for heart failure between evaluation periods (mean 
number of cardiac drugs increased from 1.7 ± 1.0 
to 2.7 ± 0.05, P = 0.041). Mean heart rate decreased 
(105 ± 14 to 84 ± 13 beats/min, p = 0.016), as did 
pulmonary wedge pressure (23 ± 8 to 12 ± 4 mm Hg, 
p = 0.012). There were no significant changes in cardiac 
index (3.1 ± 0.8 to 2.9 ± 1.0 liters/min), end-diastolic 
dimension (62 ± 13 to 62 ± 12 mm) or fractional short-
Mason et al. (1) reported on a group of patients with dilated 
cardiomyopathy who had unsuspected myocarditis dem•
onstrated by right ventricular endomyocardial biopsy. Some 
of these patients appeared to respond to immunosuppressive 
therapy. Since this report, there has been increased interest 
in the diagnosis of myocarditis in patients with clinical car•
diomyopathy in the hope of offering an alternative form of 
therapy. To date, several series reporting small numbers of 
patients with myocarditis have emphasized largely positive 
responses to immunosuppressive therapy (2-7). We de•
scribe a group of patients who have not demonstrated this 
positive response and have in fact developed serious side 
effects from treatment with azathioprine plus prednisone. 
Methods 
Patient selection. From September 1982 to July 1984, 
71 patients underwent endomyocardial biopsy at the Oregon 
Health Sciences University. Of these, 39 patients underwent 
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ening (11 ± 6 to 12 ± 3%) with treatment. Compli•
cations from immunosuppressive therapy included se•
vere soft tissue infection, acute psychosis and adrenal 
insufficiency in one patient each. 
The benefits from prednisone and azathioprine in this 
group of patients have not been demonstrated. Although 
heart rate and pulmonary wedge pressure decreased, 
these changes could be ascribed to increases in the con•
ventional therapy for heart failure. Finally, there is a 
high incidence of side effects from prednisone and aza•
thioprine therapy. These findings suggest that this un•
proven therapy for myocarditis should be limited to ex•
perimental protocols. 
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biopsy as part of their evaluation for unexplained dilated 
cardiomyopathy. At least five individual biopsy samples 
were obtained for light microscopic studies for each patient. 
Histologic results for seven patients were consistent with 
chronic lymphocytic myocarditis. One of these patients had 
active systemic lupus erythematosus and was excluded from 
further analysis. The remaining six are presented in this 
report. 
Protocol. At the time of initial biopsy, patients under•
went right heart catheterization with thermodilution cardiac 
output determination, systemic arterial pressure measure•
ment (by way of the radial or brachial artery) and two•
dimensional and two-dimensional-directed M-mode echo•
cardiography. These measurements were repeated after 3 
months of therapy. 
The treatment protocol consisted of azathioprine, 1.5 
mg/kg body weight per day, and prednisone, 60 mg per 
day, for 1 month. The dose of prednisone was then de•
creased by 5 mg/week to a maintenance dose of 20 mg/day. 
All 3 month studies were performed with the patients re•
ceiving azathioprine, 1.5 mg/kg per day and prednisone, 20 
mg/day. 
Histology. The histologic diagnosis of myocarditis was 
based on lymphocyte infiltration (>5 cells per high power 
field), myocyte destruction or degeneration and replacement 
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with fibrosis. Biopsy samples were evaluated for infiltration 
with inflammatory cells, fibrosis and necrosis and graded 0 
(absent) to 3 (extensive) for each variable. 
Results 
Clinical features. The ages of the three male and three 
female patients ranged from 19 to 50 years (mean 30). Total 
symptom duration ranged from 1 to 55 months (five of the 
six patients had symptoms for less than 10 months). One 
patient had fever, five demonstrated jugular venous disten•
sion, three had rales, five had a third heart sound and two 
demonstrated peripheral edema. Cardiomegaly by chest x•
ray film and left ventricular hypertrophy by electrocardio•
gram were each present in five. The demographic data were 
not substantially different from data in the remaining 32 
patients (22 men, 10 women) without myocardial inflam•
mation, 9 of whom were less than 35 years of age and 10 
of whom had symptoms for less than 1 year. 
Table 1 demonstrates the number of cardiac medications 
(glycosides, diuretic drugs and vasodilators) administered 
in addition to the immunosuppressive agents, and the hemo•
dynamic and histologic variables in the six patients during 
the two study states (before and during immunosupressive 
therapy). The mean number of cardiac medications in•
creased during therapy from 1. 7 ± 1. 0 to 2.7 ± 0.05 
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(p = 0.041). Only two patients had no change in their 
"conventional" therapy. 
Hemodynamic changes. There were no significant dif•
ferences in mean arterial or right atrial (p = 0.12) pressure 
between study times; however, pulmonary wedge pressure 
decreased during therapy (p = 0.012) and heart rate de•
creased from 105 ± 14 to 84 ± 13 beats/min (p = 0.016). 
There were no differences in stroke volume index or cardiac 
index between study periods. 
All patients demonstrated diffuse, nonsegmental reduc•
tion in systolic function. There were no group differences 
in end-diastolic dimension or fractional shortening between 
treatment states. Left ventricular wall thickness was also 
unchanged (10 ± 1 versus 11 ± 2 mm, respectively). 
Pathologic findings. The initial pathologic findings in 
the six patients are as follows: Patient 1 demonstrated mild, 
diffuse, primarily interstitial inflammatory infiltration. There 
was a diffuse increase in interstitial collagen replacing nor•
mal myocardium and no definitive active necrosis. Patient 
2 demonstrated a moderate diffuse inflammatory infiltrate 
with scattered areas of active necrosis. There was also an 
increase in interstitial collagen (Fig. 1). Patient 3 demon•
strated extensive diffuse myocardial round cell infiltration. 
There was a large focal area of myocyte degeneration (Fig. 
2). Patient 4 also demonstrated primarily a diffuse pattern 
of inflammation with occasional foci of round cells sur-
Table 1. Hemodynamic and Histologic Findings Before and During Immunosuppressive Therapy 
No. Cardiac Drugs MAP (mm Hg) RAP (mm Hg) PCW (mm Hg) HR (beats/min) SVI (mllm2) 
Patient Before During Before During Before During Before During Before During Before During 
I 2 3 127 113 4 7 18 12 116 90 24 27 
2 0 2 73 93 4 2 14 6 100 75 46 37 
3 2 3 120 100 12 I 36 13 120 90 26 52 
4 3 3 91 III 10 6 23 12 114 96 21 20 
5 2 2 86 92 10 5 19 15 84 90 32 35 
6 I 3 73 85 10 8 27 16 96 60 29 40 
Mean 1.7 2.7 95 99 8 5 23 12 105 84 30 35 
SO 1.0 0.5 23 II 3 3 8 4 14 13 9 11 
P Value 0.041 NS 0.12 0.012 0.016 NS 
CI 
(liters/min per m2) EDD (mm) FS (%) Inflammation Fibrosis 
Patient Before During Before During Before During Before During Before During 
I 2.8 2.4 37 47 23 11 I I 2 2 
2 4.6 2.8 62 64 10 11 2 0 3 
3 3.1 4.7 74 80 6 14 3 I 
4 2.4 1.9 59 50 10 16 3 2 
5 2.7 3.2 66 64 10 14 2 1 2 2 
6 2.8 2.4 71 66 10 9 2 0 3 I 
Mean 3.1 2.9 62 62 11 12 2.2 1.0 1.8 1.5 
SO 0.8 1.0 13 12 6 3 0.8 0.6 0.8 0.5 
P Value NS NS NS 0.034 NS 
CI = cardiac index; EDD = end-diastolic dimension; FS = fractional shortening; HR = heart rate; MAP = mean arterial pressure; p = probability; 
PCW = pulmonary wedge pressure; RAP = mean right atrial pressure; SO = I standard deviation; SVI = stroke volume index. 
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Figure 1. Patient 2. Endomyocardial biopsy section demonstrat•
ing interstitial inflammatory cell infiltrate (arrowheads) (X 200, 
reduced by 40%). 
rounding degenerating myocytes (Fig. 3). Patient 5 had a 
moderate diffuse inflammatory infiltrate and in addition had 
several foci of clumps of lymphocytes and occasional poly•
morphonuclear cells, associated with myocytolysis with 
degenerating myocyte nuclei. The inflammatory pattern in 
Patient 6 was also diffuse with interstitial fibrosis present. 
The degree of inflammation decreased in most patients (mean 
grade 2,2 ± 0.8 before treatment versus 1.0 ± 0.6 during 
treatment, p = 0.034). There were no significant changes 
in the amount of fibrosis seen in the biopsy samples obtained 
in the two study states. 
Complications from immunosuppressive therapy oc•
curred in three of our six patients, and included acute psy•
chosis, a severe soft tissue infection and adrenal insuffi•
ciency after surgery for a strangulated hernia. All three 
patients were successfully treated. 
Discussion 
Immunosuppressive therapy and ventricular func•
tion. We have demonstrated a lack of improvement in ven•
tricular systolic function in this small group of patients with 
myocarditis. We used ejection phase indexes-specifically, 
fractional shortening-to determine systolic performance. 
Although ejection phase indexes are sensitive to changes in 
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Figure 2. Patient 3. Endomyocardial biopsy section showing ex•
tensive round cell infiltration into the myocardium (small arrow•
heads) and a large area of myocyte degeneration (large arrow•
head) (x 300, reduced by 40%). 
afterload (8), the absence of change in mean atrial pressure, 
cardiac size (end-diastolic dimension) and wall thickness 
suggests that major alteration in afterload did not occur 
between study states. 
The decreases in heart rate and pulmonary wedge pres•
sure are consistent with a lessening of heart failure, but are 
more likely secondary to the additional conventional therapy 
rather than the administration of azathioprine and predni•
sone. An additional factor that would be partially respon•
sible for the decrease in heart rate was the noticeable de•
crease in anxiety during the follow-up studies in most patients. 
Comparison with previous reports. Although the em•
phasis of this report differs from that of most previous series, 
the results are not strikingly different. Two of our six pa•
tients had mild improvement in measured fractional short•
ening and five of the six had lessening of congestive symp•
toms. Mason et al. (1) reported improvement in 5 of their 
10 patients treated with immunosuppression; however, the 
means of assessing improvement were not noted. Edwards 
et al. (2) reported improvement in one of four patients as•
sessed clinically. O'Connell et al. (3) demonstrated improve•
ment in ejection fraction in 6 of 15 patients with a positive 
cardiac gallium scan. Biopsy was not performed in these 
patients; however, subsequently this group (9) reported good 
800 HOSENPUD ET AL. 
IMMUNOSUPPRESSION IN MYOCARDITIS 
Figure 3. Patient 4. Endomyocardial biopsy sections. A, Several 
areas of interstitial round cell infiltration (arrowheads) (X 300); 
B, increased magnification of endomyocardial section (X 680) 
showing a cluster of lymphocytes surrounding a degenerating myo•
cyte (arrowhead) (A and B reduced by 40%). 
correlation between gallium scan and myocardial biopsy. 
Fenoglio et a1. (4) noted improvement in 7 of 20 patients 
with myocarditis; however, only four of these patients had 
objective evidence (ejection fraction) of systolic improve•
ment. Zee-Cheng et a1. (5) reported clinical improvement 
in 5 of 11 patients with myocarditis treated with Imuran 
and prednisone; again, no objective assessment of systolic 
performance was presented. A preliminary, somewhat more 
encouraging report from Strain et a1. (6) showed improve•
ment in ejection fraction in five of seven patients with my•
ocarditis receiving immunosuppression. None of these stud•
ies used control patients and none reported an analysis of 
conventional therapy. Most recently, Dec et a1. (10) reported 
on a group of patients with clinical dilated cardiomyopathy, 
18 of whom had myocarditis. There was no apparent dif•
ference between the nine patients treated with immuno•
suppression and the nine who were not so treated. Moreover, 
there was no difference between the improvement rate of 
those with myocarditis and that of patients with histologic 
cardiomyopathy, of whom 40% showed spontaneous 
improvement. 
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Histologic criteria of myocarditis. One potential prob•
lem with our series and similar series of patients with myo•
carditis is the histologic criteria utilized in making the di•
agnosis of myocarditis. This concern is reflected in the vastly 
differing incidence rates of the disease in the various series 
(range of 3 to 63% of patients with dilated cardiomyopathy) 
(1,5). We utilized the criteria defined by Edwards et a1. (2) 
of greater than five lymphocytes per high power field and 
evidence of myocardial injury. Moreover, our 15% inci•
dence rate of myocarditis in patients with clinical dilated 
cardiomyopathy more closely agrees with the experience of 
other centers (personal communication) and reported series 
(2,4,10). 
Adequacy of immunosuppressive technique. Finally, 
we used moderate doses of prednisone (60 mg/day) and 
azathioprine (1.5 mg/kg per day) for immunosuppression in 
our patients. The lack of response could thus possibly· be 
related to inadequate therapy. Prednisone dosages reported 
(1-3) range from 40 mg/day to 60 mg/m2 per day depending 
on the series and therefore clearly have not been standard•
ized. Evidence for the adequacy of our therapy resides pri•
marily with the follow-up (3 month) biopsy samples. A 
prednisone/azathioprine lymphocytolic response is sug•
gested by the reduction in inflammatory cell infiltrate in the 
myocardium seen in the majority of patients. Moreover, the 
very high complication rate seen at these moderate doses 
would not support increasing the amount of immuno•
suppression. 
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Conclusion. Our results and those of previous investi•
gations offer little evidence to support use of azathioprine 
and prednisone to treat patients with dilated cardiomyopathy 
associated with myocardial lymphocyte infiltration (myo•
carditis). Because these medications carry significant side 
effects, efficacy should be demonstrated by a randomized 
study before this form of therapy becomes standard for 
patients with this disease. 
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